Radiation Therapy in Treating Women With Stage I or Stage II Breast Cancer

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Radiation Therapy Oncology Group
ClinicalTrials.gov Identifier:
NCT00002873
First received: November 1, 1999
Last updated: July 17, 2013
Last verified: February 2008
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: No date given
  Primary Completion Date: June 2007 (Final data collection date for primary outcome measure)
Publications:
Rabinovitch R, Winter K, Taylor M, et al.: Toxicity and cosmesis from RTOG 95-17: a phase I/II trial to evaluate brachytherapy as the sole method of radiation therapy for stage I and II breast carcinoma. [Abstract] Breast Cancer Res Treat 106 (1): A-4078, S192-3, 2007.
Arthur DW, Winter K, Kuske RR, et al.: A phase II trial of brachytherapy alone following lumpectomy for select breast cancer: tumor control and survival outcomes of RTOG 95-17. [Abstract] Int J Radiat Oncol Biol Phys 66 (3 Suppl 1): A-51, S29-30, 2006.
Kuske RR, Winter K, Arthur DW, et al.: A phase II trial of brachytherapy alone following lumpectomy for stage I or II breast cancer: initial outcomes of RTOG 9517. [Abstract] J Clin Oncol 22 (Suppl 14): A-565, 18s, 2004.
Kuske RR, Winter K, Arthur D, et al.: A phase I/II trial of brachytherapy alone following lumpectomy for select breast cancer: toxicity analysis of Radiation Therapy Oncology Group 95-17. [Abstract] Int J Radiat Oncol Biol Phys 54(2 suppl 1): A-151, 87, 2002.